SLU-PP-332
Pan-ERR agonist sold as an 'exercise mimetic'
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Pan-ERR agonist often described as an exercise mimetic. The published dose is murine — from mice — and the conversion to humans is not established. It differs from the mitochondrial peptides in being a small molecule, with oral and injectable planning.
Quick reference
- Class
- Pan-ERR agonist, small molecule. Described as an exercise mimetic.
- Routes
- Oral tablet and injectable.
- Published dose
- Murine (mouse). No established human conversion.
- Status
- Not approved. No human data.
Capsule vs injection — which format?
| Study | Duration | Dose & Route | Outcome (Mouse) |
|---|---|---|---|
| Billon 2023 — endurance | 15 days | 25 mg/kg intraperitoneal, 1×/day | Increased treadmill endurance; acute aerobic exercise transcriptional signature in muscle. |
| Billon 2023 — chronic | 28 days | 50 mg/kg intraperitoneal, 2×/day | Raised oxidative muscle fibers and OXPHOS proteins; longer running distance before exhaustion. |
| Billon 2024 — DIO mice | 28 days | 50 mg/kg intraperitoneal, 2×/day | Reduced fat mass; improved glucose tolerance; lower triglycerides. |
| Billon 2024 — ob/ob mice | 12 days | 50 mg/kg intraperitoneal, 2×/day | Improved metabolic markers in the ob/ob model. |
| Xu 2024 — heart failure | 6 weeks | IP dosing (Burris-lab standard) | Improved ejection fraction; reduced fibrosis; increased survival in the TAC model. |
| Wang 2023 — aging kidney | 8 weeks | 25 mg/kg intraperitoneal, 1×/day | Reduced albuminuria; preserved podocin; restored mitochondrial function. |
Capsule vs injection — which format?
| Approach | Duration | Review point | Best for |
|---|---|---|---|
| Short reference | 4 weeks | Week 4 | Initial research planning window aligned with the shortest published mouse studies. |
| Standard | 6–8 weeks | Week 6 | Matches Billon 2023/2024 chronic mouse exposure windows. |
| Extended | 12 weeks | Week 8 and Week 12 | Longest community oral pattern; no human safety data beyond preclinical exposures. |
SLU-PP-332 Reconstitution Guide
| Vial size | BAC water added | Concentration | 250 mcg | 500 mcg | 1 mg | 5 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1.0 mL | 5,000 mcg/mL | 5 units (0.05 mL) | 10 units (0.10 mL) | 20 units (0.20 mL) | 100 units (1.00 mL) |
| 5 mg | 2.0 mL | 2,500 mcg/mL | 10 units (0.10 mL) | 20 units (0.20 mL) | 40 units (0.40 mL) | Full vial |
| 5 mg | 3.0 mL | 1,667 mcg/mL | 15 units (0.15 mL) | 30 units (0.30 mL) | 60 units (0.60 mL) | — |
| 10 mg | 2.0 mL | 5,000 mcg/mL | 5 units (0.05 mL) | 10 units (0.10 mL) | 20 units (0.20 mL) | 100 units (1.00 mL) |
| 10 mg | 5.0 mL | 2,000 mcg/mL | 12.5 units (0.125 mL) | 25 units (0.25 mL) | 50 units (0.50 mL) | — |
| 20 mg | 5.0 mL | 4,000 mcg/mL | 6 units (0.06 mL) | 12.5 units (0.125 mL) | 25 units (0.25 mL) | 125 units (1.25 mL) |
SLU-PP-332 Timeline & What to Monitor
| Window | What was measured | Where |
|---|---|---|
| Hours | Acute aerobic exercise transcriptional signature in skeletal muscle after a single 25 mg/kg IP dose. | Billon 2023. |
| 15 days | Increased treadmill endurance at 25 mg/kg IP daily. | Billon 2023. |
| 28 days | Raised oxidative muscle fibers and OXPHOS proteins; ~25-30% fat-mass reduction in DIO mice at 50 mg/kg BID. | Billon 2023 / Billon 2024. |
| 6 weeks | Improved ejection fraction, reduced fibrosis, and increased survival in pressure-overload heart failure. | Xu 2024. |
| 8 weeks | Reduced albuminuria, preserved podocin, restored mitochondrial function in aging kidney tissue. | Wang 2023. |
SLU-PP-332 vs MOTS-c vs AOD-9604
| Attribute | SLU-PP-332 | MOTS-c | AOD-9604 |
|---|---|---|---|
| Class | Synthetic small-molecule pan-ERR agonist | Mitochondrial-derived peptide (16 aa) | Modified GH fragment (aa 176-191) |
| Primary target | ERRα / β / γ nuclear receptors | AMPK activation and mitochondrial signaling | Lipolysis pathways without GH-receptor signaling |
| Half-life | Not formally published; 6-hour exposure seen in mouse plasma/muscle | ~3 hours (mouse plasma) | ~2-4 hours (rodent data) |
| Dosing frequency | BID preclinical; QD community oral or SC | Daily SC, often 5 days on / 2 off | Daily SC |
| Max studied dose | 50 mg/kg 2×/day (mouse, 28 days) | 5-15 mg/kg (mouse) | 1-5 mg/day in human Phase 2 |
| Peak efficacy signal | ~25-30% fat-mass reduction in DIO mice over 28 days | Improved insulin sensitivity in aged mice | Modest fat-loss signal in human Phase 2; primary endpoint missed |
| Human route | Oral tablet or SC in community use; no validation | SC in community use; no human efficacy trials | SC in clinical trials |
| FDA status | Not approved; no human trials | Not approved; no native human trials | Not approved for fat loss; Phase 2 failed primary endpoint |
| Unique advantage | Only pan-ERR agonist with demonstrated in-vivo exercise-mimetic activity | Endogenous mitochondrial peptide with AMPK-focused signaling | Most human clinical history of the three |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.